Lucy Kilburn
0000-0002-1987-7545
Institute of Cancer Research
110 papers found
Refreshing results…
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Adherence to the consort statement in early breast cancer (EBC) randomized controlled trials (RCTs) in systemic treatment: a systematic review
Defining endpoints for recurrence in randomised controlled trials (RCTs) of systemic therapy for early breast cancer (EBC): A call for standardisation
Has the consolidated standards of reporting trials (CONSORT) statement improved the publication quality of early stage breast cancer (EBC) randomised controlled trials (RCTs) of systematic treatment: a systematic review.
First mature survival analysis of the Intergroup Exemestane Study: A randomised trial in disease-free, postmenopausal patients with early breast cancer randomized to continue tamoxifen or switch to exemestane following an initial 2-3 years of adjuvant tamoxifen.
First mature analysis of the Intergroup Exemestane Study
First mature analysis of the Intergroup Exemestane Study (IES)
Tamoxifen washout - the effect on safety in the intergroup exemestane study (IES).
Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) - 2 year bone mineral density (BMD) and bone biomarker data
Concordance of intrinsic subtyping and risk of recurrence (ROR) scores between matched primary and metastatic tissue from Triple Negative Breast Cancer Trial (TNT)
Missing publications? Search for publications with a matching author name.